Summary At histopathological diagnosis of non-Hodgkin's lymphoma (NHL) the mean number of mitoses in 10 high power fields (x40) was determined in thin sections (2ym) and designated 'mitotic index' (MI) It is concluded that the assessment of mitoses in NHL gives prognostic information in addition to histopathologic classification. The method is simple and the proliferative activity and histopathological diagnosis can be ascertained routinely on the same occasion.
Summary At histopathological diagnosis of non-Hodgkin's lymphoma (NHL) the mean number of mitoses in 10 high power fields (x40) was determined in thin sections (2ym) and designated 'mitotic index' (MI) . In 38 patients the thymidine labelling index (LI) of the lymphoma cells was also determined. There was a close correlation between MIs and LIs (r=0.81, P<0.001) indicating that MI reflects the proliferative activity in NHL. Among 101 patients with NHL classified according to the Kiel nomenclature MIs were generally lower in lymphomas of low grade malignant type than in the high grade malignant lymphomas. The variation of MIs within morphological subgroups was especially pronounced in high grade lymphomas. Only 18 of 49 patients (37%) with MI.2 have survived for 2 years in contrast to 37 of 52 patients (77%) with MI<2 (P=0.001). For patients with histologically low grade lymphomas and MI.2.0 the median survival was 23 months and for those with MI<2.0 58 months (P=0.09). Patients with high grade lymphomas and MI>2.0 had a median survival of 15 months compared to 57 months for those with MI <2.0 (P= 0.04). In a multivariate analysis of 50 patients with centroblastic-centrocytic (CB-CC) or centroblastic (CB) lymphomas the importance of different prognostic factors was analysed. Among the variables age, MI, growth pattern (follicular vs. diffuse), cell type (CB-CC vs. CB), clinical stage (I vs. II-IV), initial chemotherapy (active vs. less active) only age and MI gave significant prognostic information.
It is concluded that the assessment of mitoses in NHL gives prognostic information in addition to histopathologic classification. The method is simple and the proliferative activity and histopathological diagnosis can be ascertained routinely on the same occasion.
In non-Hodgkin's lymphoma (NHL) histopathologic classification is of importance for evaluation of prognosis and choice of therapy. Among the various systems for classification used, the Kiel classification (Lennert, 1978) has proven valuable for these purposes (Cavallin-Stahl et al., 1981; Glimelius et al., 1983; Brittinger et al., 1984) .
According to the results from several studies the determination of the proliferative activity of lymphoma cells gives considerable prognostic information in addition to morphologic classification. In these studies uptake of thymidine (Brandt et al., 1981; Costa et al., 1981; Kval0y et al., 1985) or the determination of cells in Sphase by flow cytometry (Roos et al., 1985) have been used to assess the proliferative activity of the lymphoma tissue.
In the present work the number of mitoses has been assessed in biopsy material from patients with NHL classified according to the Kiel classification. The prognostic importance of the method has been evaluated by analysis of survival of the patients.
Materials and methods

Patients
The material comprises 107 patients with NHL diagnosed in [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] . In 6 patients the biopsy material was not considered optimal for an assessment of the number of mitoses. Thus 101 patients were included in the study. There were 54 men and 47 women aged 31-89 years (median 66 years). Twenty-three patients presented with a single involved site-11 with a nodal site and 12 with an extranodal lesion. The remaining 78 patients were in stage II-IV. All patients were followed for a minimum of two years or until death. Followup was performed in our hospital or in close collaboration with other hospitals in our region.
Histopathologic examination
Five gm sections were cut from the biopsy specimens and (x 40) . The total number of mitotic figures was divided by ten and the quotient was designated mitotic index (MI). In order to evaluate the reliability of MI, the number of mitoses was recorded on two occasions in 10 patients. On the second determination the pathologist was unaware of the outcome of the first assessment of MI. All determinations of MI were performed by one pathologist (M.A).
Determination of labelling index
Material from the lymphomas was obtained through aspiration. Cell suspensions were incubated with tritiated thymidine and the percentage labelled lymphoid cells (LI) was determined in autoradiography preparations as described previously (Brandt et al., 1981) .
Staging procedures Clinical staging was performed according to the Ann Arbor classification (Carbone et al., 1971) . The staging procedures have been described previously (Brandt et al., 1981) Patients with low grade malignant lymphomas were generally treated with either CVP (cyclophosphamide, vincristine and prednisone) or prednimustine, a chlorambucil ester of prednisolone. In those patients treated with CVP and/or prednimustine, who did not respond to treatment, the treatment was changed to CHOP or MEV.
Since the patients were diagnosed within a fairly long period of time, treatment has not been uniform. In the analysis of the impact of MI compared to other prognostic factors (see below) the initial therapeutic regimens were therefore dichotomized into intense (CHOP, CHOP+metho-trexate and MEV) and less intense (CVP and prednimustine). Table I . In each patient the difference between the two MIs was small, on average 0.7. (Figure 1 ).
There was a significant correlation between the number of mitoses recorded and the number of cells in S phase as determined by LI (r= 0.81, P<0.001).
MI and morphology The MIs in various morphologic subgroups of NHL are shown in Figure 2 . In low grade malignant lymphomas MIs were generally low and there was only a small variation of MI within the various morphologic groups. The centrocytic (CC) lymphomas constituted an exception with a marked heterogeneity. There were no obvious differences in MIs when comparing follicular versus diffuse growth pattern in CB-CC lymphomas.
In the high grade malignant lymphomas there was a considerable variation in MIs suggesting a great variation in proliferative activity.
MI and survival
In NHL a large proportion of patients surviving the first 2 years after diagnosis will be long term survivors (Leonard et al., 1983) . Forty-six patients have died within two years. The median MI for these patients was 2.8. For the 55 patients who have survived for more than two years the median MI was 1.3 ( Figure 3) For patients with low grade malignant lymphomas and MI<2 the median survival was 58 months and for those with MI_2 median survival was 23 months (Figure 4) . The difference does not reach statistical significance (P=0.09). For the patients with high grade malignant lymphomas and MI<2 the median survival was 57 months compared to 15 months for those with MI .2 (P= 0.04, Figure 5) .
A separate analysis of the prognostic impact of MI was performed in the patients with follicle center cell lymphomas (FCC) of the CB-CC and centroblastic (CB) subtypes. This group comprised 50 patients after exclusion of 3 patients who died from intercurrent disease. Age and MI were used as continuous variables. with high grade some pitfalls; the number of lymphoma cells may vary in different parts of a section. This is apparently not a serious drawback since the results of repeated determinations of MI were fairly constant. Another objection is that MI is not strictly related to the number of cells in the visual fields. In the large cell lymphomas, which constitute the high grade malignant group, the number of cells examined in 10 visual fields will naturally be lower than in the low grade malignant lymphomas. This might cause a relative underestimation of the MI in high grade malignant lymphomas. Low MIs with only small differences among patients in the same subgroup were recorded in lymphocytic lymphomas and immunocytomas. There was a relatively wide range of variation of MIs in the CB-CC group and among the CC lymphomas there was considerable heterogeneity. The highest MI were recorded in lymphomas of high grade malignant type, and there was a striking variation in MI within the various subgroups. These findings are in good agreement with reports on the proliferative activity in NHL using other methods (Brandt et al., 1981 , Barlogie et al., 1983 , Costa et al., 1981 Christensson, 1983; Hansen et al., 1981; Roos et al., 1985; Gerdes et al., 1984) .
The MI is obviously related to survival. About half of the patient material had a MI>2.0. Only 37% of these patients have survived for more than two years whereas 71% of the patients with MI<2.0 are alive more than two years after diagnosis. Low grade malignant lymphomas with MI>2.0 were associated with a shorter median survival time compared to low grade malignant lymphomas with MI<2.0. In high grade malignant lymphomas survival was significantly shorter for the patients with a MI.2.0 than for those with a lower MI. Although the number of patients in each subgroup of low grade and high grade lymphomas was rather small, the results suggest that MI offers prognostic information in addition to the Kiel histopathological classification. It remains to be determined whether the assessment of MI is also valuable using other schemes of classification, e.g., the Working Formulation.
According to the Kiel nomenclature the follicle center cell (FCC) lymphomas constitute a large part of the NHL and the CB-CC (low grade) and CB (high grade) types are most common (Glimelius & Sundstrom, 1982; Brittinger et al., 1984) . The distinction between these two types of lymphomas may sometimes be uncertain. Moreover, it is sometimes difficult to ascertain whether the growth pattern is follicular, follicular and diffuse or entirely diffuse. Such distinctions might also be of prognostic importance. co tested for in comparison to MI. Age and MI turned out to be significant predictive factors and the others did not add further information. Thus the proliferative activity of CB-CC and CB lymphomas appears to be an independent prognostic variable.
With current treatment programs a low proliferative activity of lymphoma cells is compatible with long term survival (Brandt et al., 1981; Costa et al., 1981; Gronowitz et al., 1983; Kval0y et al., 1985; Roos et al., 1985) . For patients with rapidly proliferating lymphomas, new therapeutic regimens are needed. A prompt and simple evaluation of the mitotic activity in histological preparations may help to select these patients for future therapeutic trials.
